#Japan #Minato-ku, Tokyo #Regeneosome #Good Hero #Euglena

Enhancing Virus Vector Production with Ergothioneine

In a significant advancement in the field of gene therapy, Regeneosome Corporation, a subsidiary of Space Seed Holdings, has teamed up with Good Hero Therapeutics (GHT) and Euglena Co., Ltd. to file a patent for a novel method that enhances the production efficiency of viral vectors using the rare amino acid ergothioneine. This collaborative effort focuses on tackling the prominent barriers related to the high manufacturing costs and low production efficiency of viral vectors, particularly for adeno-associated viruses (AAV), which are widely used in gene therapy.

Background: Overcoming the Manufacturing Bottlenecks in Gene Therapy

As gene therapy continues to evolve rapidly, the production of high-quality viral vectors has become a major challenge. The need for affordable and scalable production methods is critical, as the lack of such technology hinders widespread implementation of gene therapies. Recognizing this global urgency, Regeneosome and GHT have formed a strategic partnership aimed at addressing these critical manufacturing bottlenecks.

The collaboration was established following the introduction of GHT's innovative techniques for improving AAV vector production. By leveraging Euglena's potential candidates that can enhance AAV productivity, the research team discovered that ergothioneine significantly increases the efficiency of viral vector production.

The Invention: Anti-Aging Component Boosts Vector Production

The newly developed technology integrates ergothioneine, known for its potent antioxidant properties, into the culture systems of viral vector-producing cells. Experimental results have demonstrated that adding ergothioneine during a 72-hour cultivation period led to a marked increase in viral titer compared to control groups. This breakthrough indicates that ergothioneine not only supports cellular health but also optimizes production capabilities of therapeutic viral vectors.

Future Developments: Supporting GHT and Longevity Applications

Building on this patent technology, Regeneosome plans to provide robust support for GHT as they develop and deploy processes related to gene therapy drug manufacturing. GHT has already garnered recognition for its advanced techniques, having been supported by government initiatives. Additionally, Regeneosome envisions applying this innovative technology in the field of longevity, targeting the enhancement of healthspan and the mitigation of aging-related issues. Research will continue to explore how these advancements can reshape the future of medical solutions by controlling genetic functions affected by aging.

About Regeneosome Corporation

Regeneosome is committed to addressing aging challenges through biotechnology, utilizing nanoparticles such as exosomes to innovate solutions in regenerative medicine. By deeply analyzing the exosomes produced by various cells and designing these nanoparticles at a molecular level, Regeneosome seeks to illuminate how these particles function within biological systems. This initiative is ultimately aimed at developing medical technologies that contribute not only to extending healthspan but also to the advancements in space medicine, hence, fostering humanity's journey into space. For more information, visit Regeneosome.

About Space Seed Holdings

Space Seed Holdings operates with the mission of making science fiction a reality by engaging in investment, research, and the creation of innovative enterprises within the space-focused deep-tech sector. Through its “Fermentation and Longevity Fund” program, the company aims to support the societal implementation of fermentation and longevity technologies while addressing global challenges. The overarching goal is to compile the necessary technologies by 2040 to enable human habitation in outer space, collaborating with various stakeholders along the way. For further details, visit Space Seed Holdings.